drugset / Trial / NCT02176252

Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects

NCT02176252

Phase 1 Completed 83 enrolled Ardelyx AstraZeneca · collab
NaSingle-groupQuadruple-blindTreatment

Summary

The study is designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of AZD1722 in healthy Japanese subjects at increasing doses given for 7 days in order to allow for including Japanese subjects in future global studies. A cohort of Caucasian subjects will be included in the study to evaluate cardiac effects, assessed by digital ECGs (dECG) recordings, also in Caucasian subjects.

Timeline

Start
2013-07
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenapanor Small molecule 15 mg
Subject Tenapanor Small molecule 30 mg
Subject Tenapanor Small molecule 60 mg
Subject Tenapanor Small molecule 90 mg
Subject Tenapanor Small molecule 180 mg

Indications

No indication recorded.